205242-66-6

Basic information

• Product Name: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine
• Synonyms: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine;(2S)- 2-[(Phenylmethoxy)methyl]-4-(phenylmethyl)morpholine;(S)-2-[(Phenylmethoxy)methyl]-4-(phenylmethyl)morpholine;(S)-4-benzyl-2-((benzyloxy)methyl)morpholine hydrochloride
• CAS NO: 205242-66-6
• Molecular Formula: C₁₉H₂₃NO₂
• Molecular Weight: 297.39142
• Mol File: 205242-66-6.mol

Chemical Properties

• Boiling Point: 415.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.095
• PKA: 6.26±0.10(Predicted)
• CAS DataBase Reference: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine(205242-66-6)
• EPA Substance Registry System: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine(205242-66-6)

Safety Data

• Hazardous Substances Data: 205242-66-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine is used as a building block in organic synthesis for the creation of various biologically active molecules. Its presence of benzyl and benzyloxy groups allows for a wide range of chemical reactions, making it a valuable component in the synthesis of complex organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine is utilized as a key intermediate in the development of new drugs and fine chemicals. Its unique structure and functional groups contribute to the design and synthesis of potential therapeutic agents, enhancing the discovery of novel pharmaceuticals.
Used in Medicinal Chemistry:
(S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine also finds applications in medicinal chemistry, where it serves as a precursor for the synthesis of compounds with potential therapeutic properties. Its versatility in chemical reactions and compatibility with various functional groups make it an attractive candidate for the development of new medicinal agents.
Used in Drug Development:
In the field of drug development, (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine plays a crucial role as a starting material for the synthesis of drug candidates. Its unique structural features and reactivity enable the design and synthesis of innovative pharmaceuticals with improved efficacy and selectivity, ultimately contributing to the advancement of healthcare.

Upstream product

• 205242-64-4 (2S)-1(benzylamino)-3-(benzyloxy)propan-2-ol 
• 2133-07-5 2-(benzylamino)ethyl hydrogen sulfate 
• 2930-05-4 (S)-benzyl glycidyl ether 
• 100-46-9 benzylamine 
• 14618-80-5 (R)-benzyl glycidol 
• 205242-65-5 (S)-4-Benzyl-6-benzyloxymethyl-morpholin-3-one 

Downstream Products

• 132073-83-7 (S)-morpholin-2-ylmethanol 
• 132073-84-8 (S)-4-trityl-2-hydroxymethylmorpholine 
• 135912-25-3 Toluene-4-sulfonic acid (S)-4-trityl-morpholin-2-ylmethyl ester 
• 919286-71-8 tert-butyl (2S)-2-(bromomethyl)-4-morpholinecarboxylate 

Relevant articles and documents

METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY

Invented is the use of 1 H-imidazo[4,5-c]pyridin-2-yl compounds in the treatment of specified cancers.

INHIBITORS OF AKT ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

(R)-(+)-2-[[[3-(morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine methanesulfonate: A new selective rat 5-hydroxytryptormine(1b) receptor antagonist

In the search for new 5-hydroxytryptamine (5-HT) receptor antagonists it was found that the compound (R)-(+)-2-[[[3-(morpholinomethyl)-2H-chromen-8- yl]oxy]methyl]morpholine methanesulfonate, (R)-25, is a selective rat 5- hydroxytryptamine(1B) (r5-HT(1B)) receptor antagonist. The binding profile showed a 13-fold preference for r5-HT(1B) (Ki = 47 ± 5 nM; n = 3) vs bovine 5-HT(1B) (Ki = 630 nM; n = 1) receptors. The compound had very low affinity for other monoaminergic receptors examined. The r5-HT(1B) receptor antagonism was demonstrated by the potentiation of the K+-stimulated release of [3H]- 5-HT from superfused rat brain slices in vitro, an effect that was antagonized by addition of 5-HT to the superfusion fluid. (R)-25 at 20 mg/kg sc enhanced the 5-HT turnover in four rat brain regions (hypothalamus, hippocampus, striatum, and frontal cortex) with about 40% measured as the 5- HTP accumulation after decarboxylase inhibition with 3- hydroxybenzylhydrazine. At 3 mg/kg sc (R)-25 produced a significant increase in the number of wet dog shakes in rats, a 5-HT(2A)/5-HT(2C) response that was abolished by depletion of 5-HT after pretreatment with the tryptophan hydroxylase inhibitor p-chlorophenylalanine. The observations show that (R)- 25, by inhibiting terminal r5-HT(1B) autoreceptors, increases the 5-HT turnover and the synaptic concentration of 5-HT.